Tobacco Reduction Efforts, Intravitreal Injections Shown to Improve AMD Patients’ QOL in Japanese Study

A national analysis of the Japanese population highlights the burden of AMD-related vision impairment and the effect tobacco use has on disease burden. Awareness for tobacco control and healthcare equity is warranted to reduce the burden leading to moderate and severe visual impairments as well as blindness, researchers say. Photo: Carolyn Majcher, OD. Click image to enlarge. The Global Burden of Disease study, as the name suggests, highlights the impact specific diseases have on an international and regional scale. Investigators can use this study to examine trends in prevalence and disease burden over periods of time and predict how diseases can affect particular populations in the future.Using data from 1990 to 2021, researchers made a prediction for the burden of age-related macular degeneration (AMD) on a Japanese population out to 2040. They examined the prevalence, disability-adjusted life years (DALYs) and temporal trends of vision impairment caused by disease over the two-decade dataset. For context, analyzing DALYs calculates the burden of disease. Notably, tobacco users were analyzed for their contribution to the burden of vision impairment caused by AMD.Since 1990, the number of patients in Japan with AMD-related vision impairments rose by 159%. This trend continued for DALYs, which increased by 134%. However, after calculating age-standardized rates for both prevalence and DALYs, researchers reported a decline in results over time. Prevalence rates went down from 22.3 to 19.7 per 100,000 individuals within the Japanese population, and DALY rates reduced from 2.3 to 1.9 per 100,000 individuals.An analysis on the burden of AMD-related vision impairment in relation to sex and age was conducted. Women reported higher prevalence rates than men, even though rates from both groups declined from 1990 to 2021. The number of AMD cases with vision categorized as moderate, severe or blind was reported as well. Moderate cases grew from 15,288 in 1990 to 45,186 in 2021. Severe cases increased from 3,617 to 9,186. Reports of blindness rose from 17,122 to 38,938. Rates for severe and blind cases decreased over time (2.2 to 2.1 per 100,000 individuals and 10.6 to 8.1 per 100,000 individuals), but researchers noted that moderate rates were mostly stable from 1990 to 2021.When analyzing data from tobacco users, researchers observed a decline in DALY rate over time, from 0.4 per 100,000 individuals in 1990 to 0.2 per 100,000 individuals in 2021. DALYs decreased from 15.2% to 9.7%, an overall decline of 36.3%.“This trend may be closely linked to Japan’s progressively strengthened tobacco control policies over recent decades, including increases in tobacco taxes, legislative restrictions on smoking in public places, and gender-specific tobacco control strategies,” suggested the researchers in their paper. “Japan approved the World Health Organization Framework Convention on Tobacco Control over two decades ago, and its nationwide tobacco control measures have shown early success.”Of course, the advent of anti-VEGF therapy also “played a critical role in reducing the burden of vision impairment attributable to AMD,” concluded the researchers. “Future efforts should focus on promoting cost-effective diagnostic and treatment strategies, strengthening tobacco control measures, and implementing comprehensive interventions targeting modifiable risk factors.”Click here for the journal source. Huang L, Cong L, Grzybowski A. Tobacco-attributable age-related macular degeneration vision impairment in Japan: A national and prefecture-level analysis from 1990 to 2040. Transl Vis Sci Technol 2026;15:2:23.  This article was developed by the editorial staff in conjunction with experts in the field. In the process, AI may have been among the editorial tools used to meet the goals of human editors, who approved all content.